LONDON (Reuters) -Eli Lilly will raise the list price in the UK of its weight-loss and type 2 diabetes treatment Mounjaro by 170% to be in line with other European markets, the U.S. drugmaker said on Thursday.

Lilly launched Mounjaro in the UK in February last year, while rival Novo Nordisk’s Wegovy treatment has been available in the country since September 2023.

The new price is effective from September. The price for a month’s supply of the highest dose of the medicine will increase from £122 to £330, Lilly said.

In the UK, mirroring dynamics elsewhere, especially in the United States, Lilly challenged Novo’s first-mover advantage swiftly after launching. By late 2024, Mounjaro sales outstripped those of Wegovy in the booming online pharmacy market for the medicines, Reuters reported

See Full Page